$1.370
-0.010 (-0.72%)Al cierre
Noticias de CRIS
Eventos de CRIS
Curis Prices Public Offering of 3.73 Million Shares, Raising Approximately $5.6 Million
Curis announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the company and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of $1.50 per share and accompanying common warrant. The common warrants will have an exercise price of $1.75 per share, will be exercisable immediately and will expire five years from the issuance date. The pre-funded warrants will have an exercise price of $0.01 per share and will be exercisable immediately until exercised in full. The gross proceeds from the Offering are expected to be approximately $5.6M, before deducting placement agents fees and estimated Offering expenses payable by Curis. The Offering is expected to close on or about August 14. A.G.P./Alliance Global Partners is acting as the lead placement agent and Laidlaw & Company is acting as co-placement agent in connection with the Offering.
Curis Announces Enrollment Progress in TakeAim CLL Study
On June 26, Curis announced that eleven clinical sites had opened for enrollment in the TakeAim CLL study. Curis is announcing that it has consented the first six patients in that study - and reaffirmed its guidance for the dosing of five CLL patients by the end of July, with initial CLL data expected in December.
Curis Trading Halted, News Pending
Curis trading halted, news pending
Curis Initiates 11 Clinical Sites for CLL Study
Curis announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia. The company also reaffirmed its guidance for the dosing of the initial five patients in the TakeAim CLL study by the end of July, with data expected in December 2026. In addition, the company reported that its stockholders approved a reverse stock split proposal at the special meeting of stockholders held on June 25. Stockholders approved a proposal to effect a reverse stock split of its issued and outstanding shares of common stock at a ratio ranging from 1-for-5 to 1-for-25, in furtherance of the company's regaining compliance with Nasdaq's $1.00 bid price rule, said Curis, which adds that the company intends to announce the specific ratio and effective date in advance of the reverse stock split becoming effective.
Curis Expects Cash to Support Operations into Second Half of 2027
Curis believes its cash and cash equivalents as of March 31 of $15.0M, together with anticipated gross proceeds of up to an additional $20.2M from the exercise of the January 2026 PIPE Financing Series B Warrants upon the public announcement of dosing the 5th CLL patient in our TakeAim CLL study expected later this year, should enable the Company's planned operations into the second half of 2027.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.